The customer reported a lower than expected prostate-specific antigen (access hybritech psa) result for one (1) patient on the access 2 immunoassay system (serial number (b)(4)).The physician questioned the initial result as the patient was known to have previously elevated access hybritech psa results.On (b)(6) 2015 the patient's prostate-specific antigen (psa) was tested at a reference laboratory (quest diagnostics) on an alternate methodology (siemens) and a higher result above the normal reference range was obtained.The customer stated the initial access hybritech psa result was reported outside the laboratory.There was no report of patient injury or change in patient treatment associated with this event.The customer noted that quality control (qc), assay calibration, a precision test and system check were performing within specifications at the time of the event.The patient's sample was collected in a serum tube and analyzed from a 2ml sample cup.The sample was centrifuged at 3,250 rpm (revolutions per minute) for ten (10) minutes at room temperature.The customer did not report any issues with sample integrity.
|